Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis

Area of Science:

• Hepatology
• Virology
• Pediatric Gastroenterology

Background:

• Chronic hepatitis B (CHB) is a significant global health concern in children.
• Effective antiviral therapies are crucial for managing pediatric CHB and preventing long-term complications.
• Interferon-alpha (IFN-alpha) has been explored as a treatment option for CHB.

Purpose of the Study:

• To evaluate the efficacy of recombinant interferon-alpha (IFN-alpha) in treating chronic hepatitis B in pediatric patients.
• To assess the impact of IFN-alpha on viral replication, viral markers, and biochemical parameters.
• To identify factors influencing treatment response in children with CHB.

Main Methods:

• A meta-analysis was conducted on six randomized clinical trials.
• Included 240 pediatric patients with chronic hepatitis B treated with IFN-alpha.
• Analyzed virological (HBV DNA, HBeAg clearance) and biochemical (ALT normalization) endpoints.

Main Results:

• IFN-alpha effectively blocked viral replication and reduced HBV DNA levels.
• Hepatitis B e antigen (HBeAg) clearance was observed in some patients.
• Alanine aminotransferase (ALT) normalization occurred in a significant portion of treated children.
• Prolonged therapy (> 6 months) correlated with better virological and biochemical responses.
• High IFN-alpha dosages did not yield superior outcomes.
• Children with elevated ALT levels showed a better treatment response.

Conclusions:

• Recombinant IFN-alpha demonstrates efficacy in managing chronic hepatitis B in children by reducing viral load and improving liver enzymes.
• Prolonged treatment duration is a key factor for successful outcomes, whereas dosage intensity is less critical.
• Limitations include potential bias from limited follow-up and the absence of data on histological response and hard clinical outcomes like cirrhosis or hepatocellular carcinoma.